Wang Jin-Wen, Chen Yun-Dai, Wang Chang-Hua, Yang Xin-Chun, Zhu Xiao-Ling, Zhou Zi-Qiang
Department of Cardiology, Chinese PLA General Hospital, 100853 Beijing, PR China.
Cardiology. 2013;124(3):153-60. doi: 10.1159/000346386. Epub 2013 Mar 8.
The 'no-reflow' phenomenon after a primary percutaneous coronary intervention (pPCI) in patients with acute ST-segment elevation myocardial infarction (STEMI) is a strong predictor of both short- and long-term mortality. We therefore developed and prospectively validated a risk score system in order to identify STEMI patients at high risk in terms of no-reflow after primary PCI.
The first part of our study used data from 1,615 STEMI patients who underwent primary PCI within 12 h from symptom onset. Using logistic regression, we derived a risk score to predict angiographic no-reflow using baseline clinical variables. From this score, we developed a simplified fast-track screen that can be used before reperfusion. In the second part of our study, we prospectively validated the score system using receiver-operating characteristic (ROC) curves with data from 692 STEMI patients.
The model included six clinical items: age, neutrophil count, admission plasma glucose, β-blocker treatment, time-to-hospital admission and Killip classes. The risk score system demonstrated a good risk prediction with a c-statistic of 0.757 (95% CI 0.732-0.781) based on ROC analysis.
A simple risk score system based on clinical variables is useful to predict the risk of developing no-reflow after pPCI in patients with STEMI.
急性ST段抬高型心肌梗死(STEMI)患者在接受直接经皮冠状动脉介入治疗(pPCI)后出现的“无复流”现象是短期和长期死亡率的有力预测指标。因此,我们开发并前瞻性验证了一种风险评分系统,以识别原发性PCI术后发生无复流高风险的STEMI患者。
我们研究的第一部分使用了1615例症状发作后12小时内接受原发性PCI的STEMI患者的数据。通过逻辑回归,我们得出了一个风险评分,以使用基线临床变量预测血管造影无复流情况。根据该评分,我们开发了一种可在再灌注前使用的简化快速筛查方法。在研究的第二部分,我们使用来自692例STEMI患者的数据,通过受试者工作特征(ROC)曲线前瞻性验证了该评分系统。
该模型包括六个临床项目:年龄、中性粒细胞计数、入院时血浆葡萄糖、β受体阻滞剂治疗、入院时间和Killip分级。基于ROC分析,风险评分系统显示出良好的风险预测能力,c统计量为0.757(95%CI 0.732 - 0.781)。
基于临床变量的简单风险评分系统有助于预测STEMI患者pPCI后发生无复流的风险。